Protagenic Therapeutics Files 2025 Proxy Statement

TL;DR

Protagenic's 2025 proxy statement is in, shareholders get to vote on company matters.

AI Summary

Protagenic Therapeutics, Inc. filed a definitive proxy statement on January 3, 2025, for its annual meeting. The filing details the company's governance and executive compensation, with no fee required for this filing. The company was formerly known as Atrinsic, Inc., New Motion, Inc., and MPLC, Inc.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership, voting matters, and executive compensation, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new financial or operational information that would inherently increase risk.

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Registrant
• Atrinsic, Inc. (company) — Former Company Name
• NEW MOTION, INC. (company) — Former Company Name
• MPLC, Inc. (company) — Former Company Name
• 20250103 (date) — Filing Date

FAQ

Key Financial Figures

• $25 billion — anagement (“Chancellor”), a $25 billion money management firm. While at Chancel
• $3B — p in September 2003. Invus manages over $3B of capital, with a primary focus is on
• $2 billion — quities portfolio, overseeing more than $2 billion of assets. Mr. Barrage holds a BA from

Filing Documents

• formdef14a.htm (DEF 14A) — 686KB
• 0001493152-25-000288.txt ( ) — 688KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 31 PAY VERSUS PERFORMANCE DISCLOSURE 32

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 44 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 46 STOCKHOLDER PROPOSALS 47 WHERE YOU CAN FIND ADDITIONAL INFORMATION 47 OTHER MATTERS 47 APPENDIX A: FORM OF AMENDMENT TO THE 2016 EQUITY INCENTIVE PLAN 2 PROTAGENIC THERAPEUTICS, INC. 149 FIFTH AVENUE, SUITE 500 NEW YORK, NY 10010 PROXY FOR VIRTUAL ANNUAL MEETING OF STOCKHOLDERS To be held on February 21, 2025 This proxy statement contains information related to the Annual Meeting of Stockholders of Protagenic Therapeutics, Inc., a Delaware corporation located at 149 Fifth Avenue, New York, New York 10010 (the “ Company ”), to be held on February 21, 2025 at 10:00 a.m. Eastern Time. The Annual Meeting will be completely virtual. The Annual Meeting shall be held at such other time and place to which the Annual Meeting may be adjourned or postponed. If you plan to participate in the virtual meeting, please see the instructions under “How can I attend the Annual Meeting?” on page 4 of this proxy statement. Stockholders will be able to listen, vote, and submit questions from their home or from any remote location that has internet connectivity. Stockholders may only participate online by logging in at www.virtualshareholdermeeting.com/PTIX2024 . In accordance with the “e-proxy” rules approved by the Securities and Exchange Commission (“ SEC ”) and in connection with the solicitation of proxies by our Board of Directors of Protagenic Therapeutics, Inc. (the “ Board ”), on or about January 2, 2025 we will send a Notice of Internet Availability of Proxy Materials and provide access to our proxy materials (consisting of this proxy statement, our Annual Report on Form 10-K for the year ended December 31, 2023 and a form of proxy) over the internet to each stockholder entitled to vote at the Annual Meeting. We intend to mail to requesting stockholders fu

View Full Filing

View this DEF 14A filing on SEC EDGAR